This site is intended for healthcare professionals

Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. announce FDA approval of Eprontia oral solution.

Read time: 1 mins
Published:9th Nov 2021
Eton Pharmaceuticals, Inc and Azurity Pharmaceuticals, Inc. announced that the FDA has approved Eprontia (topiramate) oral solution, 25 mg/mL.

Eprontia has been approved as a monotherapy for treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; an adjunctive therapy for treatment of partial-onset seizures, primary generalized tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as a preventive treatment of migraine in patients 12 years of age and older.

Eprontia is the first oral liquid formulation of topiramate to be approved by the FDA. Azurity will be responsible for commercializing the product and anticipates product availability before year end. Eton will receive a $5 million milestone payment upon Eprontia's commercial launch, a royalty on net sales, and potential commercial milestones.

Condition: Epilepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.